Abstract:
Background: Fluoroquinolones are among the most widely prescribed antibiotics. However,
concerns about increasing resistant microorganisms and the risk of dysglycemia associated with
the use of these agents have emerged.
Objective: The primary objective of the study was to evaluate the appropriate use of commonly
prescribed fluoroquinolones, including appropriate indication, dose, dose adjustment in
renal impairment, and duration of treatment. The secondary objective was to investigate the
dysglycemic effect of fluoroquinolone use (hypoglycemia and/or hyperglycemia) in diabetic
and nondiabetic patients.
Methods: A prospective observational study at a teaching hospital in Lebanon was conducted
over a 6-month period. A total of 118 patients receiving broad-spectrum fluoroquinolones
(levofloxacin, ciprofloxacin, and moxifloxacin) were identified. Patients were mainly recruited
from internal medicine floors and intensive care units.
Results: The final percentage for the appropriate indication, dose, and duration of fluoroquinolone
therapy was 93.2%, 74.6%, and 57.6%, respectively. A total of 57.1% of the patients
did not receive the appropriate dose adjustment according to their level of renal impairment. In
addition, dysglycemia occurred in both diabetic and nondiabetic patients. Dysglycemia was more
frequently encountered with ciprofloxacin (50.0%), followed by levofloxacin (42.4%) and moxifloxacin
(7.6%). Hyperglycemia was more common than hypoglycemia in all groups. The highest
incidence of hyperglycemia occurred with levofloxacin (70.0%), followed by ciprofloxacin
(39.0%) and moxifloxacin (33.3%). In contrast, hypoglycemia did not occur in the ciprofloxacin
group, but it was more common with moxifloxacin (11.1%) and levofloxacin (6.0%).
Conclusion: The major clinical interventions for the future will adjust the dose and duration
of therapy with commonly prescribed fluoroquinolones. The incidence of hypoglycemia was
less common than hyperglycemia.
Citation:
Kabbara, W. K., Ramadan, W. H., Rahbany, P., & Al-Natour, S. (2015). Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia. Therapeutics and clinical risk management, 11, 639-647.